Atrium Therapeutics
RNARNA · Stock Price
Historical price data
Overview
Atrium Therapeutics is a clinical-stage biotech focused on pioneering precision RNA medicines for the heart. The company emerged as a spinoff from Novartis's acquisition of Avidity Biosciences, launching with approximately $270 million to advance its novel cardiac-targeted AOC delivery platform. Its strategy is to address the high unmet need in rare genetic cardiomyopathies, with an IND filing for its lead candidate, ATR 1072, planned for H2 2026. Under CEO Kath Gallagher, Atrium combines deep RNA and rare disease expertise to transform cardiology from symptom management to curative genetic intervention.
Technology Platform
A proprietary Antibody Oligonucleotide Conjugate (AOC) platform designed to deliver RNA therapeutics (siRNA/ASO) directly to heart muscle cells via monoclonal antibody targeting, aiming to overcome cytotoxicity, immunogenicity, and redosing limitations.
Pipeline
11| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Rivastigmine + Placebo (for rivastigmine) | Parkinson's Disease | Approved | |
| Phenoxybenzamine + Doxazosin | Pheochromocytoma | Approved | |
| Ropivacaine HCL + Exparel + Epinephrine + Clonidine HCL + Ke... | Renal Carcinoma | Phase 3 | |
| Metformin Hydrochloride ER | Sarcoma Metastatic | Phase 2 | |
| Diclofenac | Wobenzym | Phase 2 |
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Competes with AAV-based gene therapy companies (e.g., Tenaya Therapeutics) in genetic cardiology and broader RNA therapeutics firms. Key differentiator is the potentially safer, re-dosable AOC platform for precise cardiomyocyte delivery, a capability few others have demonstrated.